All In Biotech

Drug Trial Radar · NCT05369052

Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)

A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 865 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

865

Planned (sponsor's estimate)

Start

May 3, 2022

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
MicuRxIndustry
Sponsor type
Industry
First posted
May 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects with moderate or severe DFI.

Conditions

  • Diabetic Foot Infection

Interventions

  • contezolid acefosamil (IV)/contezolid (PO)Drug

    Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)

  • Linezolid (IV and PO)Drug

    Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by InvestigatorsTime frame: Day 35
  2. Adverse events - symptoms reported by subjectsTime frame: 28-35 days after End-of-Therapy (EOT)
  3. Clinical laboratory assessment - complete blood countTime frame: 28-35 days after End-of-Therapy (EOT)
  4. Vital signs - heart rateTime frame: 28-35 days after End-of-Therapy (EOT)

Locations

14 sites in 8 countries. Site status is shown where the registry gives one.

  • New Hope Research Development

    Corona, California · Recruiting

  • ILD Research Center

    Vista, California · Recruiting

  • MHAT Sveti Nikolay Chudotvorets EOOD

    Lom, Bulgaria · Recruiting

  • Multiprofile Hospital for Active Treatment - KANEV

    Rousse, Bulgaria · Recruiting

  • Medical Institute Ministry of Interior Central Clinical Base

    Sofia, Bulgaria · Recruiting

  • University Multidisciplinary Hospital for Active Treatment and Emergency Medicine 'N. I. Priogov´

    Sofia, Bulgaria · Recruiting

  • South-Estonian Hospital Ltd.

    Võru, Estonia · Recruiting

  • LTD High Technology Hospital Med Center

    Batumi, Georgia · Recruiting

  • JSC Vian - West Georgia Medical Center

    Kutaisi, Georgia · Recruiting

  • GMV Care& Research - Maria Cecilia Hospital

    Cotignola, Italy · Recruiting

  • Daugavpils Regional Hospital

    Daugavpils, Latvia · Recruiting

  • Instytut Medycyny Wsi im. W. Chodzki

    Lublin, Poland · Recruiting

  • PODEMA Sp. z o.o.

    Warsaw, Poland · Recruiting

  • University Clinical Center Kragujevac

    Kragujevac, Serbia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.